LyphoMed's bretylium tosylate
Executive Summary
The injectable product in dosage of 100 mg/ml in a 10 ml vial (1,000 mg total drug content) is ANDA suitable, FDA said. Reference drug is LyphoMed's bretylium tosylate 50 mg/ml in a 10 ml vial (500 mg total drug content).